We recently published a list of Jim Cramer Commented On These 6 Stocks Recently. In this article, we are going to take a look ...
Shares of Eli Lilly & Co. LLY slid 4.73% to $869.58 Friday, on what proved to be an all-around positive trading session for ...
Compounders had been allowed to produce and sell hundreds of thousands of their own versions of popular anti-obesity drugs, ...
Pharmaceutical giant expects the move will create 3,000 high-skilled jobs and provide work for approximately 10,000 ...
A federal court in Texas has rejected a request by producers of compounded drugs to extend their ability to manufacture ...
Eli Lilly, the maker of blockbuster weight loss and diabetes drugs Zepbound and Mounjaro, said it will invest an additional ...
Polen Capital, an investment management company, released its “Polen Focus Growth Strategy” fourth quarter 2024 investor ...
Eli Lilly Chief Executive David Ricks annual compensation rose to $29.2 million in 2024, a 10% increase from the $26.2 million he received a year earlier.
The partnership comes as telehealth companies grapple with restrictions on the sale of some compounded GLP-1s.
Eli Lilly is seeking to further cement its stance as a leader in weight loss drugs in an ad campaign calling out “unapproved” medications.
Eli Lilly said it plans to build three new plants in the United States to make the key ingredients used in pharmaceuticals, ...
Eli Lilly has launched new 7.5 mg and 10 mg single-dose vials of Zepbound (tirzepatide), priced at $499 per month under the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results